Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering

  • Holger Fleischmann, Rüdiger Göke, Peter Bramlage
  • Diabetes & Metabolic Syndrome Clinical Research & Reviews, November 2017, Elsevier
  • DOI: 10.1016/j.dsx.2016.12.014

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Peter Bramlage